Survival‐Assured Liver Injury Preconditioning (SALIC) Enables Robust Expansion of Human Hepatocytes in Fah –/– Rag2 –/– IL2rg –/– Rats

Although liver‐humanized animals are desirable tools for drug development and expansion of human hepatocytes in large quantities, their development is restricted to mice. In animals larger than mice, a precondition for efficient liver humanization remains preliminary because of different xeno‐repopulation kinetics in livers of larger sizes. Since rats are ten times larger than mice and widely used in pharmacological studies, liver‐humanized rats are more preferable. Here, Fah–/–Rag2–/–IL2rg–/– (FRG) rats are generated by CRISPR/Cas9, showing accelerated liver failure and lagged liver xeno‐repopulation compared to FRG mice. A survival‐assured liver injury preconditioning (SALIC) protocol, which consists of retrorsine pretreatment and cycling 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC) administration by defined concentrations and time intervals, is developed to reduce the mortality of FRG rats and induce a regenerative microenvironment for xeno‐repopulation. Human hepatocyte repopulation is boosted to 31 ± 4% in rat livers at 7 months after transplantation, equivalent to approximately a 1200‐fold expansion. Human liver features of transcriptome and zonation are reproduced in humanized rats. Remarkably, they provide sufficient samples for the pharmacokinetic profiling of human‐specific metabolites. This model is thus preferred for pharmacological studies and human hepatocyte production. SALIC may also be informative to hepatocyte transplantation in other large‐sized species.

[1]  C. Rice,et al.  Expansion, in vivo–ex vivo cycling, and genetic manipulation of primary human hepatocytes , 2020, Proceedings of the National Academy of Sciences.

[2]  Xiaonan Zhang,et al.  A two-step lineage reprogramming strategy to generate functionally competent human hepatocytes from fibroblasts , 2019, Cell Research.

[3]  T. Ochiya,et al.  Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes , 2019, bioRxiv.

[4]  Yohan Kim,et al.  Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells. , 2019, Journal of hepatology.

[5]  L. Hui,et al.  In Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity. , 2018, Cell stem cell.

[6]  C. Rice,et al.  Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids , 2018, Cell.

[7]  B. Ekser,et al.  Interspecies chimeric livers: A step closer to solving the problem of transplantable organ shortage? , 2018, Journal of hepatology.

[8]  H. Nakauchi,et al.  Chimeric liver transplantation reveals interspecific graft remodelling. , 2018, Journal of Hepatology.

[9]  Xu Zhou,et al.  Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens , 2018, Cell Research.

[10]  T. Hibi,et al.  A Pre-Clinical Large Animal Model of Sustained Liver Injury and Regeneration Stimulus , 2018, Scientific Reports.

[11]  S. Ohta,et al.  Chimeric mice with humanized liver: Application in drug metabolism and pharmacokinetics studies for drug discovery. , 2017, Drug metabolism and pharmacokinetics.

[12]  R. Ehman,et al.  Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1. , 2017, The American journal of pathology.

[13]  M. Grompe.  Fah Knockout Animals as Models for Therapeutic Liver Repopulation. , 2017, Advances in experimental medicine and biology.

[14]  L. Hui,et al.  Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I , 2016, Scientific Reports.

[15]  M. Manns,et al.  Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. , 2016, Cancer cell.

[16]  E. Cuppen,et al.  Generation and characterization of rat liver stem cell lines and their engraftment in a rat model of liver failure , 2016, Scientific Reports.

[17]  K. Jishage,et al.  Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice , 2015, PloS one.

[18]  S. Strom,et al.  Amelioration of Hyperbilirubinemia in Gunn Rats after Transplantation of Human Induced Pluripotent Stem Cell-Derived Hepatocytes , 2015, Stem cell reports.

[19]  M. Grompe,et al.  Extensive double humanization of both liver and hematopoiesis in FRGN mice , 2014, Stem cell research.

[20]  A. Schambach,et al.  RAG1/2 Knockout Pigs with Severe Combined Immunodeficiency , 2014, The Journal of Immunology.

[21]  S. Nyberg,et al.  Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease. , 2014, Stem cell research.

[22]  K. Sekine,et al.  The development of humanized liver with Rag1 knockout rats. , 2014, Transplantation proceedings.

[23]  S. Strom,et al.  Mice with human livers. , 2013, Gastroenterology.

[24]  K. Yoshizato,et al.  A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next? , 2013, Expert opinion on drug metabolism & toxicology.

[25]  K. Yoshizato,et al.  Repopulation of the immunosuppressed retrorsine‐treated infant rat liver with human hepatocytes , 2013, Xenotransplantation.

[26]  T. Tsunoda,et al.  Morphological and microarray analyses of human hepatocytes from xenogeneic host livers , 2013, Laboratory Investigation.

[27]  S. Nyberg.  Bridging the gap: Advances in artificial liver support , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  T. Serikawa,et al.  Generation and characterization of severe combined immunodeficiency rats. , 2012, Cell reports.

[29]  C. Rice,et al.  A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. , 2011, Gastroenterology.

[30]  M. Suematsu,et al.  The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. , 2011, Biochemical and biophysical research communications.

[31]  H. Jacob,et al.  Rats! , 2009, Disease Models & Mechanisms.

[32]  Aarati R. Ranade,et al.  Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice , 2007, Nature Biotechnology.

[33]  M. Bonin,et al.  Differential gene expression in periportal and perivenous mouse hepatocytes , 2006, The FEBS journal.

[34]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[35]  R. McCuskey,et al.  Kupffer cells participate in early clearance of syngeneic hepatocytes transplanted in the rat liver. , 2002, Gastroenterology.

[36]  Anne E Kwitek,et al.  Multifactorial genetics: Rat genetics: attachign physiology and pharmacology to the genome , 2002, Nature Reviews Genetics.

[37]  D. Tyrrell,et al.  Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.

[38]  C. Rogler,et al.  Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus , 2001, Hepatology.

[39]  R. Tanguay,et al.  The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. , 1997, Biochemical and biophysical research communications.

[40]  M. Grompe,et al.  Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I , 1996, Nature Genetics.

[41]  S. Lindstedt,et al.  Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I , 1995, Nature Genetics.

[42]  R. Palmiter,et al.  Replacement of diseased mouse liver by hepatic cell transplantation. , 1994, Science.

[43]  P. Miranda,et al.  Species Differences in the Metabolism and Disposition of Antiviral Nucleoside Analogues: 2. Zidovudine , 1992 .

[44]  R. Gebhardt.  Metabolic zonation of the liver: regulation and implications for liver function. , 1992, Pharmacology & therapeutics.